WIP1 Antibody

What is WIP1 and what are its primary cellular functions?

WIP1, also known as PPM1D (protein phosphatase, Mg2+/Mn2+ dependent 1D), functions in DNA damage pathways and the regulation of cell proliferation. The human WIP1 protein has a canonical length of 605 amino acids with a molecular mass of 66.7 kilodaltons, with two identified isoforms. It localizes in both the nucleus and cytoplasm and is expressed in various tissues including the caudate, tonsil, and adrenal gland. Alternative names include IDDGIP, JDVS, and PP2C-DELTA .

Recent research has revealed that WIP1 plays a significant role in DNA repair through homologous recombination (HR). It interacts with the BRCA1-BARD1 complex and promotes correct recruitment of BRCA1 to chromatin regions flanking DNA lesions. Additionally, WIP1 dephosphorylates 53BP1 at Threonine 543, which affects the interaction between 53BP1 and RIF1, thus influencing DNA repair pathway choice .

What applications are WIP1 antibodies most commonly used for in research?

WIP1 antibodies enable researchers to detect and measure the WIP1 antigen in various biological samples. Common applications include:

The selection of appropriate application depends on your specific research question, with Western Blot being the most frequently used method for WIP1 detection .

How can I optimize sample preparation for WIP1 detection?

For optimal WIP1 detection, consider the following methodological approaches:

• For nuclear extracts: Use buffers containing phosphatase inhibitors to prevent artificial dephosphorylation of WIP1 substrates

• For whole cell lysates: RIPA buffer with protease and phosphatase inhibitors works well for WIP1 extraction

• For immunofluorescence: 4% paraformaldehyde fixation generally preserves WIP1 epitopes better than methanol

• When studying DNA damage responses: Consider collection at multiple time points post-irradiation (0.5, 2, 4, 8, 24 hours) to capture dynamic responses

• For cell cycle studies: Synchronize cells or use EdU labeling to identify S-phase cells, as WIP1 function appears particularly important in S/G2 phases

Proper sample handling is critical, as repeated freeze-thaw cycles can lead to degradation of phosphorylated proteins, potentially affecting interpretation of WIP1's phosphatase activity.

How can I investigate WIP1's role in DNA damage response pathways?

To study WIP1's function in DNA damage response:

• Generate WIP1 knockout cell lines using CRISPR/Cas9 technology as demonstrated in U2OS and RPE cell models

• Include appropriate controls:

  • Complementation with wild-type WIP1 to rescue phenotypes

  • Catalytically inactive WIP1 mutant (D314A) to demonstrate phosphatase-dependent effects

• Induce DNA damage using:

  • Ionizing radiation (typical dose: 2-10 Gy)

  • Topoisomerase I inhibitor camptothecin

  • DNA crosslinking agent mitomycin C

• Assess repair kinetics by quantifying 53BP1 foci formation and resolution

• Examine cell cycle-dependent effects using EdU labeling to identify S-phase cells

Research has shown that WIP1 knockout or inhibition leads to persistence of 53BP1 foci, particularly in S-phase cells, and increases sensitivity to DNA damaging agents. This phenotype can be rescued by complementation with wild-type WIP1 but not the catalytically inactive D314A mutant .

What experimental approaches can reveal the interaction between WIP1 and BRCA1?

To investigate the WIP1-BRCA1 interaction:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate WIP1 and probe for BRCA1-BARD1

  • Perform reverse IP using BRCA1 antibodies to confirm the interaction

  • Note that this interaction appears stable and does not increase after irradiation, unlike the WIP1-53BP1 interaction

• Phosphorylation analysis:

  • Examine BRCA1 phosphorylation at Ser1524 in WIP1-proficient versus deficient cells

  • Track the dynamics of phosphorylation after DNA damage induction

  • Use phospho-specific antibodies for Western blot and immunofluorescence analyses

• Functional assessment:

  • Monitor BRCA1 recruitment to chromatin after DNA damage

  • Compare recruitment kinetics between WIP1-proficient and WIP1-inhibited cells

  • Correlate with homologous recombination efficiency using reporter assays

Research indicates that WIP1 activity affects the correct dynamics of BRCA1 recruitment to chromatin flanking DNA lesions, suggesting a functional relationship between these proteins .

How can I study the effect of WIP1 on 53BP1 phosphorylation?

To investigate WIP1's role in 53BP1 dephosphorylation:

• Use phospho-specific antibodies against 53BP1 phosphorylated at Threonine 543

• Compare phosphorylation levels between:

  • Wild-type cells

  • WIP1 knockout cells

  • Cells treated with WIP1 inhibitor (GSK2830371)

• Perform time-course experiments after DNA damage induction

• Validate antibody specificity using siRNA against 53BP1

• Conduct in vitro dephosphorylation assays using recombinant WIP1 and phosphorylated 53BP1

Research has shown significant increases in 53BP1 T543 phosphorylation in WIP1 knockout cell lines after ionizing radiation. This phosphorylation site mediates interaction with RIF1, suggesting WIP1 regulates repair pathway choice by affecting this interaction. Note that PP4C phosphatase may also target this site, with more pronounced effects observed when both phosphatases are inhibited .

What approaches can determine if WIP1 inhibition sensitizes cells to PARP inhibitors?

To assess synthetic lethality between WIP1 inhibition and PARP inhibitors:

• Cell viability assays:

  • Compare dose-response curves for PARP inhibitors (e.g., olaparib, A-966492) in:

    • Wild-type cells

    • WIP1 knockout cells

    • Cells treated with WIP1 inhibitor

    • Cells complemented with wild-type or D314A mutant WIP1

• Cell death analysis:

  • Quantify apoptosis after combined treatment with WIP1 inhibitor and PARP inhibitors

  • Compare to single-agent treatments to determine synergistic effects

• Mechanistic studies:

  • Measure DNA damage accumulation using γH2AX staining

  • Assess homologous recombination efficiency

  • Evaluate the dependency on BRCA1 status

Research has demonstrated that U2OS WIP1 knockout cell lines show increased sensitivity to olaparib, which could be rescued by complementation with wild-type WIP1 but not catalytically inactive D314A mutant. Similar effects were observed in MCF7 and RPE cell lines, suggesting a broader applicability of this approach .

Why might I observe inconsistent WIP1 detection in my experiments?

Several technical factors can affect WIP1 detection:

When optimizing WIP1 detection, include appropriate controls:

• Positive control: Cell lines known to express WIP1 (U2OS, MCF7)

• Negative control: WIP1 knockout cells

• Phosphatase inhibitor controls when studying WIP1 substrates

How can I validate the specificity of WIP1 antibodies?

Rigorous validation ensures reliable results:

• Genetic approaches:

  • Test antibody in WIP1 knockout cell lines generated by CRISPR/Cas9

  • Use siRNA-mediated knockdown of WIP1 as complementary approach

  • Verify antibody specificity in cells expressing tagged WIP1 constructs

• Biochemical validation:

  • Compare multiple antibodies targeting different epitopes

  • Perform peptide competition assays

  • Test reactivity against recombinant WIP1 protein

• Functional validation:

  • Verify expected molecular weight (66.7 kDa for human WIP1)

  • Confirm expected subcellular localization (nuclear and cytoplasmic)

  • Demonstrate expected expression patterns after DNA damage

Research publications indicate successful validation using CRISPR/Cas9-generated WIP1 knockout U2OS and RPE cell lines as negative controls .

What controls are essential when studying WIP1's role in DNA repair?

For rigorous study of WIP1 in DNA repair, include:

• Genetic controls:

  • WIP1 knockout cells (preferably multiple independent clones)

  • Complementation with wild-type WIP1 (rescue control)

  • Complementation with catalytically inactive D314A mutant (phosphatase-dependent control)

• Pharmacological controls:

  • WIP1 inhibitor (GSK2830371, typically used at 0.5 μM)

  • DNA damage inducers (ionizing radiation, camptothecin, mitomycin C)

  • PARP inhibitors (olaparib, A-966492) for synthetic lethality studies

• Cell cycle controls:

  • EdU labeling to identify S-phase cells

  • Cell cycle synchronization when applicable

  • Cell cycle markers to distinguish G1 versus S/G2 effects

• Technical controls:

  • Loading controls for Western blots (e.g., TFIIH)

  • Validated phospho-specific antibodies

  • siRNA controls for antibody validation

How should I interpret differences in DNA repair kinetics between WIP1-proficient and deficient cells?

When analyzing DNA repair in WIP1 studies:

• Quantify repair kinetics:

  • Measure persistence of DNA damage markers (γH2AX, 53BP1 foci)

  • Compare resolution kinetics between WIP1-proficient and deficient cells

  • Analyze cell cycle-specific effects (particularly in S/G2 phases)

• Assess pathway choice:

  • Evaluate BRCA1 versus 53BP1 recruitment to damage sites

  • Monitor RIF1 localization (affected by 53BP1-T543 phosphorylation)

  • Measure homologous recombination versus non-homologous end joining activity

• Correlate with functional outcomes:

  • Cell survival after DNA damage

  • Sensitivity to pathway-specific DNA damaging agents

  • Response to targeted therapies (e.g., PARP inhibitors)

Research shows that WIP1 knockout or inhibition leads to delayed disappearance of 53BP1 foci specifically in S/G2 cells after ionizing radiation, suggesting cell cycle-specific functions in homologous recombination .

What emerging applications of WIP1 antibodies might advance cancer research?

Several promising research directions include:

• Biomarker development:

  • Correlation of WIP1 expression with therapy response

  • Use of phospho-specific antibodies to track WIP1 substrate status as pharmacodynamic markers

  • Development of companion diagnostics for WIP1 inhibitor therapies

• Advanced imaging approaches:

  • Super-resolution microscopy to study WIP1 localization at DNA damage sites

  • Live-cell imaging with fluorescently-tagged WIP1 to track dynamics

  • Proximity ligation assays to visualize WIP1-substrate interactions in situ

• Translational applications:

  • Immunohistochemistry panels including WIP1 and its substrates for patient stratification

  • Monitoring phosphorylation status of WIP1 targets during clinical trials

  • Development of phospho-flow cytometry approaches for single-cell analysis

These applications could help bridge the gap between mechanistic understanding of WIP1 function and clinical translation of WIP1-targeted therapies .

How might phospho-specific antibodies advance understanding of WIP1's substrate network?

Phospho-specific antibodies could illuminate WIP1's regulatory network:

• Systematic analysis of substrate dephosphorylation:

  • Compare phosphorylation kinetics of multiple substrates (p53-S15, 53BP1-T543, γH2AX, KAP1-S824, BRCA1-S1524)

  • Determine substrate preferences and kinetic parameters

  • Identify cell-type and context-specific differences in substrate targeting

• Pathway mapping:

  • Use phospho-antibody arrays to identify novel WIP1 substrates

  • Correlate substrate phosphorylation status with DNA repair outcomes

  • Map phosphorylation-dependent protein interactions using proteomics

• Development of novel reagents:

  • Create phospho-specific antibodies against putative new WIP1 substrates

  • Develop biosensors to monitor WIP1 activity in live cells

  • Engineer substrate-trapping WIP1 mutants for interactome studies

This knowledge would enhance our understanding of how WIP1 coordinates different aspects of the DNA damage response and could reveal new therapeutic targets .